NexImmune 過去の業績

OTCPK:NEXI 収益、費用、利益 ( )USD Millions
日付	収益	G+A経費	研究開発費
30 Jun 24	-21	11	6
31 Mar 24	-26	11	11
31 Dec 23	-32	13	16
30 Sep 23	-44	14	30
30 Jun 23	-49	14	35
31 Mar 23	-57	15	42
31 Dec 22	-63	16	47
30 Sep 22	-61	16	45
30 Jun 22	-61	16	46
31 Mar 22	-57	16	42
31 Dec 21	-51	16	37
30 Sep 21	-45	15	30
30 Jun 21	-39	14	23
31 Mar 21	-35	12	19
31 Dec 20	-33	10	18
30 Sep 20	-30	9	17
31 Dec 19	-23	6	15

質の高い収益: NEXIは現在利益が出ていません。

利益率の向上: NEXIは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: NEXIは利益が出ておらず、過去 5 年間で損失は年間2.7%の割合で増加しています。

成長の加速: NEXIの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: NEXIは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。

株主資本利益率

高いROE: NEXIは現在利益が出ていないため、自己資本利益率 ( -2960.7% ) はマイナスです。

NexImmune 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Recent updates

The Nasdaq Stock Market to Delist Common Stock of NexImmune

Nasdaq Determines to Delist NexImmune Shares of Common Stock

Nasdaq Determines to Delist NexImmune Shares of Common Stock

NexImmune, Inc. announced delayed 10-Q filing

NexImmune, Inc. announced delayed annual 10-K filing

High number of new directors

NexImmune, Inc. has completed a Follow-on Equity Offering in the amount of $3.672009 million.

NexImmune Receives Notice from Nasdaq Pursuant to Nasdaq Listing Rule 5101

NexImmune, Inc. announced delayed 10-Q filing

NexImmune Regains Compliance with the Minimum Closing Bid Price Requirement

NexImmune, Inc. Approves 1 for 25 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

NexImmune, Inc. Announces Executive Changes, Effective as of September 2, 2023

NexImmune, Inc. Announces John Trainer, Chief Financial Officer to Depart, Effective September 2, 2023

New major risk - Financial position

Neximmune Announces Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-Hsct Aml At the American Society of Clinical Oncology 2023 Annual Meeting

Independent Chairman of the Board recently bought US$164k worth of stock

Price target decreased by 30% to US$2.43

High number of new directors

Independent Chairman of the Board recently bought US$96k worth of stock

Price target decreased to US$2.43

High number of new directors

NexImmune Receives Deficiency Letter from the Listing Qualifications Department of Nasdaq

NexImmune (NASDAQ:NEXI) Will Have To Spend Its Cash Wisely

Neximmune GAAP EPS of -$0.69 misses by $0.01

NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers

NexImmune gains aftermarket on IND clearance for NEXI-003 to treat HPV-related cancers

NexImmune, Inc.(NasdaqGM:NEXI) dropped from Russell 2500 Value Index

Independent Director recently bought US$298k worth of stock

Price target decreased to US$14.75

NexImmune: Selling For Under Cash Value

Here's Why We're A Bit Worried About NexImmune's (NASDAQ:NEXI) Cash Burn Situation

NexImmune Inc. Appoints Leena Gandhi to Board of Directors as a Non-Executive Director

NexImmune, Inc., Annual General Meeting, Jun 13, 2022

High number of new and inexperienced directors

Neximmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center's Herbert Irving Comprehensive Cancer Center

Neximmune, Inc. Promotes Mathias Oelke, Ph.D., to Chief Scientific Officer

NexImmune, Inc. Announces Management Changes

Independent Director exercised options to buy US$338k worth of stock.

We're Keeping An Eye On NexImmune's (NASDAQ:NEXI) Cash Burn Rate

Independent Director has left the company

NexImmune, Inc. has completed an IPO in the amount of $110.007 million.

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06